Scott Kopetz, MD, PhD, FACP

Articles

Dr Kopetz on the Future Utility of Adagrasib/Cetuximab in KRAS G12C–Mutant CRC

April 30th 2024

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC

April 26th 2024

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Dr Kopetz on Adagrasib Plus Cetuximab in KRAS G12C+ mCRC

April 19th 2024

Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.

Dr Kopetz on the Investigation of Encorafenib, Cetuximab, and Chemotherapy in mCRC

August 16th 2023

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr Kopetz on the Rationale of the BREAKWATER Study in BRAF V600Emutant mCRC

May 4th 2023

Scott Kopetz, MD, PhD, FACP, discusses the rationale for launching the phase 3 BREAKWATER trial in BRAF V600E–mutant metastatic colorectal cancer.

Dr. Kopetz on Safety Lead-in Data from the BREAKWATER Trial in BRAF V600E–Mutant mCRC

January 22nd 2023

Scott Kopetz, MD, PhD, FACP, discusses the safety lead-in data from the phase 3 BREAKWATER trial in patients with BRBRAF V600E–mutant metastatic colorectal cancer.

Dr. Kopetz on the BEACON CRC Study and Efficacy Response Analysis in mCRC

April 12th 2022

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BEACON CRC study and the subsequent efficacy response analysis in patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr. Kopetz on the Utilization of ctDNA in CRC

March 1st 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Dr. Kopetz the Current State of ctDNA Testing in CRC

January 27th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the current state of circulating tumor DNA testing in colorectal cancer.

Dr. Kopetz on the Rationale for the BREAKWATER Trial in BRAF V600E-Mutant mCRC

January 20th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Kopetz on the Design of the BEACON CRC Trial in BRAF V600E-Mutant mCRC

October 15th 2020

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Dr. Kopetz on the Rationale for the BEACON CRC Study in BRAF V600E-Mutant mCRC

July 8th 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Kopetz on Safety Data From BEACON CRC Trial in BRAF V600E-Mutant mCRC

June 23rd 2020

Scott Kopetz, MD, PhD, FACP, discusses the safety data reported from the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E-Mutant CRC

May 30th 2020

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

Dr. Kopetz on the Rationale and Design of the BEACON CRC Study in mCRC

February 22nd 2020

Scott Kopetz, MD, PhD, FACP, discusses the rationale and primary endpoints of the BEACON CRC study in BRAF V600E–mutant metastatic colorectal cancer.

Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

June 6th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC

May 21st 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

Dr. Kopetz on the Significance of Tumor Sidedness in CRC

May 13th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the significance of tumor sidedness in colorectal cancer.

Dr. Kopetz on the Rarity of Fusions in CRC

January 17th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rarity of fusions in patients with colorectal cancer (CRC).

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.